AbbVie Inc. (ABBV)
  • CONTENT
AbbVie Inc. (ABBV)
AbbVie Inc. (ABBV)
Pfizer: Added Value For A Defensive Pharma Portfolio
The terrain in biotech and pharma is getting treacherous, and it may be Big Pharmas time to shine after, in some cases, decades of consolidation. The two biggest headwinds for the pharmaceutical industry going forward appear to be political pressure on drug pricing and the effect of an…
AbbVie launches higher dose Orilissa
AbbVie (NYSE: ABBV ) and licensor Neurocrine Biosciences (NASDAQ: NBIX ) announce the commercial availability of the 200 mg twice-daily regimen (for up to six months) of ORILISSA (elagolix) for the treatment of moderate to severe pain associated with endometriosis. More news on: AbbVie…
Gilead (GILD): why this stock is undervalued
Gilead stock looks slightly undervalued at this point because the market is undervaluing Gilead’s HIV and oncology portfolios. What is the potential for this stock?
AbbVie (ABBV): Will The Stock Recover?
ABBV diverted the Rova-T program today—and that led to its stock price fall by 13%. When will the stock bounce back?